Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors

Published:2017-04-27 Issue:2 Volume:164 Page:411-419
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Kadakia Kunal C.,Kidwell Kelley M.,Seewald Nicholas J.,Snyder Claire F.,Storniolo Anna Maria,Otte Julie L.,Flockhart David A.,Hayes Daniel F.,Stearns Vered,Henry N. Lynn

Funder

American Cancer Society

National Institutes of Health

Damon Runyon Cancer Research Foundation

Fashion Footwear Association of New York/QVC Presents Shoes on Sale

Pfizer

Novartis Pharma

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s10549-017-4260-2/fulltext.html

Reference25 articles.

1. Johnston SRD, Dowsett M (2003) Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 3:821–831. doi: 10.1038/nrc1211

2. Rugo HS, Rumble RB, Macrae E et al (2016) Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol 34:3069–3103. doi: 10.1200/JCO.2016.67.1487

3. Burstein HJ, Lacchetti C, Anderson H et al (2016) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol 34:1689–1701. doi: 10.1200/JCO.2015.65.9573

4. Henry NL, Azzouz F, Desta Z et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936–942. doi: 10.1200/JCO.2011.38.0261

5. Crew KD, Greenlee H, Capodice J et al (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877–3883. doi: 10.1200/JCO.2007.10.7573

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Managing menopause after cancer;The Lancet;2024-03

2. Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone App;JCO Oncology Practice;2023-11

3. Mat Pilates and belly dance: Effects on patient-reported outcomes among breast cancer survivors receiving hormone therapy and adherence to exercise;Complementary Therapies in Clinical Practice;2023-02

4. The British menopause society consensus statement on the management of estrogen deficiency symptoms, arthralgia and menopause diagnosis in women with treated for early breast cancer;Post Reproductive Health;2022-09-01

5. Creation of an inventory of quality markers used to evaluate pharmacokinetic literature: A systematic review;Journal of Clinical Pharmacy and Therapeutics;2021-10-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3